David S. Haynes, MD
As a personal preference, I do not use aminoglycosidecontaining otic drops for chronic ear disease in my practice. But this does not necessarily mean that no one should. There are very few cases in the literature in which aminoglycos ide-contai ning drops have been impli cated as a cause of ototoxicity when they are used to treat chronic ear disease.
I have testified in several cour t cases that involved ototox icity cause d by an intrave nous aminoglycos ide. I have also serve d as an expert witness for the defense in one of the few cases in the United States in which an otolaryngologist was accused of causing irreversible ototoxicity as a result ofusi ng a topieal aminoglycos ide. My involvement in the latter case led me to conduct an extensive review of the literatur e and perform other research, which will form the basis of my arguments.
Indications for topieal aminoglycoside treatment Topieal aminoglyc osides have been used for the treatment of chronic suppurative otitis media (CSOM) . The definiti on of CSOM is somewhat controv ersial, but for the purposes of this discussion, I define it as a tympanic memb rane perforation acco mpanied by otorrhea that persists for 6 weeks or longer (although there is debate over the duration of the persistence). The incidenee of CSOM has been reported to be 39 per 100,000 children. An estimated 2 million tympanostomy tubes are placed in the United States each year, and approximately 20% of the patients require treatment for post-tympanostomy tube otorrhea . Nunez and Browning reported that the overa ll incidenee of intracra nial brain abscess in patient s with CSOM is I in 10,000; however, the lifetime risk in a 30-year-old patient is much greater: 1 in 200. I Schukn echt reported the use of intratympanic streptomycin for the treatment ofMeniere' s disease in 1957.
2 Dr. Rutka' s group in Toronto rece ntly reported their success using gentamicin transtympanically to ablate vestibular function in patients with Meniere ' s disease.' Fears of ototoxicity are not supported in the literature Aminoglycoside antibiotics can be ototoxic; of that, there is no argument. The medicolegalliterature is replete with expert testimony of this fact, as is the otolaryngology literature. The ototoxic potential of streptomycin was recognized soon after it was firs t used in the 1940s. Neomycin was developed in 1949 and gentamicin in 1963 in an attempt to avoid ototoxic ity but, of course, neither effort succee ded in this rega rd.
Nevertheless, the question remains: Areaminoglycoside antibiotics ototox ic when they are used to treat a chronieally infec ted ear ? This question has yet to be satisfac torily answered because the literature is somew hat confusingo Researchers who have conducted animal studies have used different species, different dosages, and differe nt ways of measurin g results, and most have studied uninfected ears. What ' s more, animal data are difficult to extrapolate to human s. The anatomic differences betwe en animais and human s are many. For exa mple, the round window membrane is much thick er in humans than in animais. And, of course, there are physiologic differences among the different species.
In humans, very few studies have implicated topie al aminoglycosides in ototoxicity. Most of those that have are single case reports, most involved prolonged therapy, and many involved the use of framyce tin (also known as neomycin I f), which was never approved for use in the United States. Moreover, some of these findings in these reports are tenu ous at best, because the treated patients had prolonged infections. Finally, otic drops were impl icated in some studies even though the treated patients had also undergone surgery .
The 30 patients that Dr. Rutka and colleagues treated for inadvertent ototoxicity caused by commercially ava ilable gentamicin/betamethaso ne drops represent by far the largest such population ever reported.' There are few well-controlled studies of note in the literature. In one large study publi shed in 1976, Gyde reported that of 300
Volume 82 • Suppl 1 • 13 patients with otorr hea who had been treated with gentarnicin for 3 weeks prior to surgery , none showed any evidence of ototoxicity.' In 1993, Lund y and Grah am pub1ished the resu1ts of their survey of2,235 otolaryngologists." They reported that 94% of the respondents used ototopical agen ts to treat post-tymp anostorny tube otorrhea, 84% did so to treat draining perforations, 75% used them intraopera tive ly, and 30% used thcm to treat dry perforations. Of the 2,23 5 respondents, only 3.4% reported that they had ever observed any ototoxic ity.
Widespread use attests to safety
Th e wides pread use of am inog lycos ide -co nta ini ng eardrops is a testam ent to their safety. In the 1990s, the manu facturer of polym yxin/ne omycin/hydrocorti sone (PNH) otic suspension reported that it had sold 1.5 million bottles ov er a 2-year per iod . Fu rth erm or e , man y otolaryngologists in leadership positions in the United States cont inue to use aminoglycoside drop s; some use them exc lusive ly, and some eve n use them with intraoperative packi ng.
PNH acco unts for a large share of the eardrop market in Nashville, Tenn ., which I consider to be a progressive medical city. (Nas hvi lle has a major uni versity, four large private hospitals, and a strong otology and neurotology presence). In July 200 1, PNH ' s share of the Nashvill e market was 51%. By comparison, sales of the fluoroquinolones ciprofloxacin and ofloxacin, which are not ototoxic at all, repr esented 19 and 16%, respectively, of total sa1es.
How does Nashville compare with the rest of the nation ? The co mbined market share of ciprofloxac in and ofloxacin nationwid e is 55%. Not surprisingly, otol aryngolog ists use topieal quin olones more than primary care physicians do and less than pediatrici ans do. In fact, I first learned about ciprofloxacin ophthalmic drop s from a referring pediatrician who was treatin g patient s with CSOM.
Effeet of medieolegal eoneerns on preseribing A numb er of factors influ ence our decisions as to which otic drop s we prescribe. As caregivers, we are quick to point out that our decision s are guided by c1inical experience and evidence-based medic ineoWe are less enthusiastic about admitting that economic and medicolegal co ncerns also play an imp ortant role. I have contacted a numb er of colleag ues around the country and have learned that there are at least four cases currently in litigation in which aminoglycos ide drop s are being blamed for causing ototoxicity. In Canad a, there are seve n such cases.
Infotmed con sent. These cases iIIustrate in a most profound way the importance of obtaining informed co nsent. In Canada, it has been sugges ted that all patients be warned of the possibilit y of ototox icity-specifically, hearin g loss and vertigo -be fo re they receive any arninoglycoside-cont aining dro p. Similarly, many clinics are now obtaining written infor med consent from patients who are bein g treated with steroids for sudden hearing loss, because of the possib ility that some of these patients might develop avasc ular necrosis of the hip.
As surgeo ns, we are all familiar with the necessity of obtaining written informed consent, but as prescribers of eardrops, obtaining such consent is new territory. If we do begin obtaining informed conse nt before prescribing eardrops, however, sho uld we also do so before prescribing other medic ations? Based on my own review of the literature, I have co ncluded that the incidenee of topieal aminoglycosi de-induced ototoxicity is no grea ter than 1 in 10,000-that is, 0.01 %. Most medications carry some degree of risk, and many have complication rates that are much higher than 0.01 %.
Malpractice. If a physician treating CSOM prescribes an otic drop that is used by more than 50% of his colleagues, is the physician liable for any subseq uent dru grelated complication? If a patient with sudden hearin g loss experiences avascular necrosis of the hip after receiving prop erly administered treatment, is the co mplicatio n the fault of the physician ? In some areas of the Un ited States, a failure to treat sudden hearing loss might constitute negligence. Co nversely, an adve rse reaction to treatment might constitute malpra ctice. It happens agai n and agai n.
In conclu sion, aminoglycos ide drops do have some potential for ototoxicity, but such cases are rare, and these agents co ntinue to be widely used . They can be prescribed with confidence-but not ove rconfidence ; consider obtainin g informed conse nt.
